Sophie Christin-Maitre
Sophie Christin-Maitre has a total of 183 co-authors. Here are the top co-authors by number of shared publications:
Bruno Donadille
Centre of rare diseases CRESCENDO, Endocrine Unit, Hôpital Saint-Antoine, Assistance-Publique Hôpitaux de Paris, Endo-ERN Network , 75012 Paris
5 shared publications- Camille Vatier
Assistance Publique Hôpitaux de Paris, Saint-Antoine Hospital, Reference Center of Rare Diseases of Insulin Secretion and Insulin Sensitivity (PRISIS), Department of Endocrinology, Paris, France
3 shared publications - Sylvie Jaillard
Cytogenetics and Cell Biology Department, Rennes University Hospital, Rennes, France
3 shared publications Valérie Bernard
Service d'endocrinologie, hôpital Saint-Antoine, Assistance publique-Hôpitaux de Paris, 75012 Paris, France; Sorbonne université, Paris, France
3 shared publications- Anna Lokchine
Cytogenetics and Cell Biology Department, Rennes University Hospital, Rennes, France
2 shared publications Anne Bachelot
Sorbonne Université, Service d’Endocrinologie et Médecine de la Reproduction, Centre de Référence des Maladies Endocriniennes Rares de la Croissance et du Développement (CRESCENDO), Centre de Référence des Pathologies Gynécologiques Rares (PGR), Inserm CIC 1901 Pitié Salpêtrière, Endo-ERN, Hôpital Pitié-Salpêtrière, AP-HP , Paris 75013
2 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by Oxford University Press (OUP) in Sexual Medicine
- Vol. 14 (5) , qfag074
SEXATURN: sexual function of patients with Turner syndrome compared to that of women with premature ovarian insufficiency
Introduction: Reduced sexual activity has been reported in women with Turner syndrome (TS), a chromosomal disorder frequently associated with premature ovarian insufficiency (POI), but data on sexual function and its qualitative aspects remain limited. Furthermore, few studies have compared sexual function of women with TS to that of women with POI from other etiologies (non-TS POI). Our aim was to assess sexual function in women with TS and compare it to that of women with non-TS POI, and to evaluate whether sexual dysfunction in TS is related to different comorbidities. Methods: SEXATURN is a monocentric, cross-sectional study (NCT 05223621) conducted at a French reference center for rare endocrine diseases. We included women aged 18–50 years with TS or non-TS POI. Sexual function was assessed using the abbreviated Female Sexual Function Index (FSFI-6). Clinical data were collected through questionnaires and electronic medical records. The primary outcome was the prevalence of impaired sexual function (FSFI-6 < 19). Secondary outcomes included comparison of FSFI-6 scores between TS and non-TS POI, FSFI-6 scores among sexually active patients and identification of factors associated with sexual dysfunction. Results: A total of 205 women were included (99 with TS, 106 with non-TS POI). Impaired sexual function was observed in 49.5% of women with TS and 43.4% of women with non-TS POI, without significant difference (P = .38). Among sexually active women, prevalence rates of impaired sexual function were similar (30.6% vs 31%) in both groups. Women with TS reported later sexual age of onset, fewer partners, and lower orgasm frequency. No association was found between sexual dysfunction and age, hormone replacement therapy nor TS-related comorbidities. Being single was strongly associated with impaired sexual function, particularly in women with TS (OR 8.82). Discussion: Strengths are a well-phenotyped cohort from a reference center, the use of a validated questionnaire and high response rates. Limitations include intrinsic limits of the FSFI-6, which does not assess distress or broader sexual experiences. SEXATURN study shows that women with TS exhibit reduced sexual activity but similar rates of impaired sexual function compared to women with non-TS POI. Being in a relationship is a protective factor. Our findings support the need of sexual and psychological care into multidisciplinary management of patients with TS. Trial registration: ClinicalTrial.gov (NCT 05223621) registration date January 24, 2022 and date of enrolment of the first subject December 02, 2022.
- 2 July 2026
- Published by Oxford University Press (OUP) in Sexual Medicine
- Vol. 14 (5) , qfag074
Open AccessSEXATURN: sexual function of patients with Turner syndrome compared to that of women with premature ovarian insufficiency
Introduction: Reduced sexual activity has been reported in women with Turner syndrome (TS), a chromosomal disorder frequently associated with premature ovarian insufficiency (POI), but data on sexual function and its qualitative aspects remain limited. Furthermore, few studies have compared sexual function of women with TS to that of women with POI from other etiologies (non-TS POI). Our aim was to assess sexual function in women with TS and compare it to that of women with non-TS POI, and to evaluate whether sexual dysfunction in TS is related to different comorbidities. Methods: SEXATURN is a monocentric, cross-sectional study (NCT 05223621) conducted at a French reference center for rare endocrine diseases. We included women aged 18–50 years with TS or non-TS POI. Sexual function was assessed using the abbreviated Female Sexual Function Index (FSFI-6). Clinical data were collected through questionnaires and electronic medical records. The primary outcome was the prevalence of impaired sexual function (FSFI-6 < 19). Secondary outcomes included comparison of FSFI-6 scores between TS and non-TS POI, FSFI-6 scores among sexually active patients and identification of factors associated with sexual dysfunction. Results: A total of 205 women were included (99 with TS, 106 with non-TS POI). Impaired sexual function was observed in 49.5% of women with TS and 43.4% of women with non-TS POI, without significant difference (P = .38). Among sexually active women, prevalence rates of impaired sexual function were similar (30.6% vs 31%) in both groups. Women with TS reported later sexual age of onset, fewer partners, and lower orgasm frequency. No association was found between sexual dysfunction and age, hormone replacement therapy nor TS-related comorbidities. Being single was strongly associated with impaired sexual function, particularly in women with TS (OR 8.82). Discussion: Strengths are a well-phenotyped cohort from a reference center, the use of a validated questionnaire and high response rates. Limitations include intrinsic limits of the FSFI-6, which does not assess distress or broader sexual experiences. SEXATURN study shows that women with TS exhibit reduced sexual activity but similar rates of impaired sexual function compared to women with non-TS POI. Being in a relationship is a protective factor. Our findings support the need of sexual and psychological care into multidisciplinary management of patients with TS. Trial registration: ClinicalTrial.gov (NCT 05223621) registration date January 24, 2022 and date of enrolment of the first subject December 02, 2022.
- Open Access
- 1 July 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 195 (1) , 86-95
Using machine learning to discriminate non-classical 21-hydroxylase deficiency from polycystic ovary syndrome: an external validation study
Introduction: Nonclassical 21-hydroxylase deficiency (NC21OHD) is a rare autosomal recessive disorder that is frequently misdiagnosed as polycystic ovary syndrome (PCOS) because of their overlapping clinical and biochemical presentations. The conventional diagnostic method, the cosyntropin stimulation test, is invasive, time consuming, and difficult to implement in routine clinical practice. To overcome these limitations, we previously developed a proof-of-concept machine learning model integrating basal serum steroid profiling by liquid chromatography with tandem mass spectrometry (LC–MS/MS) to identify NC21OHD without the need for dynamic stimulation testing. The present study aimed to validate and refine this model in a larger, multicentric cohort to evaluate its diagnostic performance in distinguishing NC21OHD from PCOS based on baseline steroid signatures. Methods: This tricentric study included 447 women: 263 with PCOS and 59 with NC21OHD in the training set (Pitié-Salpêtrière Hospital, Paris), and 104 PCOS and 21 NC21OHD in 2 independent validation cohorts (Saint-Antoine Hospital, Paris; Bordeaux University Hospital). Twenty serum steroids were quantified by LC–MS/MS and analyzed using orthogonal partial least squares discriminant analysis. Model robustness was assessed by internal cross-validation and external validation. Results: 20-steroid model achieved complete separation between NC21OHD and PCOS in both external validation cohorts (accuracy = 100%). The most discriminant metabolites were 21-deoxycortisone, 21-deoxycortisol, and 17-hydroxyprogesterone. Simplified 3- and 6-steroid models demonstrated reduced sensitivity (∼90%) and specificity (∼97%). Conclusion: Machine learning combined with basal LC–MS/MS steroid profiling enables accurate identification of NC21OHD without dynamic stimulation. This approach could simplify diagnosis, improve patient comfort, and support large-scale screening of hyperandrogenic women.
- 1 July 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 195 (1) , 86-95
Open AccessUsing machine learning to discriminate non-classical 21-hydroxylase deficiency from polycystic ovary syndrome: an external validation study
Introduction: Nonclassical 21-hydroxylase deficiency (NC21OHD) is a rare autosomal recessive disorder that is frequently misdiagnosed as polycystic ovary syndrome (PCOS) because of their overlapping clinical and biochemical presentations. The conventional diagnostic method, the cosyntropin stimulation test, is invasive, time consuming, and difficult to implement in routine clinical practice. To overcome these limitations, we previously developed a proof-of-concept machine learning model integrating basal serum steroid profiling by liquid chromatography with tandem mass spectrometry (LC–MS/MS) to identify NC21OHD without the need for dynamic stimulation testing. The present study aimed to validate and refine this model in a larger, multicentric cohort to evaluate its diagnostic performance in distinguishing NC21OHD from PCOS based on baseline steroid signatures. Methods: This tricentric study included 447 women: 263 with PCOS and 59 with NC21OHD in the training set (Pitié-Salpêtrière Hospital, Paris), and 104 PCOS and 21 NC21OHD in 2 independent validation cohorts (Saint-Antoine Hospital, Paris; Bordeaux University Hospital). Twenty serum steroids were quantified by LC–MS/MS and analyzed using orthogonal partial least squares discriminant analysis. Model robustness was assessed by internal cross-validation and external validation. Results: 20-steroid model achieved complete separation between NC21OHD and PCOS in both external validation cohorts (accuracy = 100%). The most discriminant metabolites were 21-deoxycortisone, 21-deoxycortisol, and 17-hydroxyprogesterone. Simplified 3- and 6-steroid models demonstrated reduced sensitivity (∼90%) and specificity (∼97%). Conclusion: Machine learning combined with basal LC–MS/MS steroid profiling enables accurate identification of NC21OHD without dynamic stimulation. This approach could simplify diagnosis, improve patient comfort, and support large-scale screening of hyperandrogenic women.
- 4 June 2026
- Published by Elsevier in Bulletin de l'Académie Nationale de Médecine
- Vol. 210 (6) , 709-714
La fonction ovarienne chez les femmes ayant un syndrome de Turner
- 4 June 2026
- Published by Elsevier in Bulletin de l'Académie Nationale de Médecine
- Vol. 210 (6) , 709-714
La fonction ovarienne chez les femmes ayant un syndrome de Turner
- 24 September 2025
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 40 (11) , 2189-2201
SWS1-complex in premature ovarian insufficiency: SWSAP1 as a new POI gene
STUDY QUESTION: What other zinc finger SWIM domain-containing protein 7 (SWS1/ZSWIM7) partners are involved in premature ovarian insufficiency (POI)? SUMMARY ANSWER: This study identifies novel pathogenic variants in zinc finger SWIM domain-containing protein 7 (SWS1/ZSWIM7) and its partner, SWSAP1, which impair interhomolog homologous recombination (IH-HR) and lead to isolated POI. WHAT IS KNOWN ALREADY: Knockout mice models of the SWS1-complex (also known as the SWS1–SWSAP1–SPIDR complex or Shu complex) are infertile due to meiotic arrest. Variants of both SWS1/ZSWIM7 and SPIDR are described in POI, but so far, no SWSAP1 variants have been described in female infertility. STUDY DESIGN, SIZE, DURATION: Screening for SWS1-complex variants was performed using exome or genome sequencing data from women with POI as ongoing patient care. In silico modelling, IH-HR assays, and western-blot analysis were performed to test the impact of novel variants identified in genes of the SWS1-complex (SWSAP1 and SWS1/ZSWIM7) on homologous recombination, protein expression, and protein interactions. PARTICIPANTS/MATERIALS, SETTING, METHODS: Five unrelated patients from France were enrolled based on their exome or genome sequencing result as part of ongoing patient care. All the patients were diagnosed with POI and met the European Society of Human Reproduction and Embryology (ESHRE) diagnostic criteria for POI. Functional validation was performed using mouse embryonic stem cells to study the impact of two novel variants found in two patients. MAIN RESULTS AND THE ROLE OF CHANCE: We report five different pathogenic or likely pathogenic variants in five patients. We report the previously described c.231_232del and c.176C>T variants in SWS1/ZSWIM7, as well as two novel variants, c.22del and c.151C>T. Additionally, we report a homozygous frameshift deletion in SWSAP1 (c.353del). All the patients display a similar phenotype of severe isolated POI, associated with primary or early secondary amenorrhea and signs of puberty delay. In silico modelling and IH-HR assays of both SWS1/ZSWIM7 c.176C>T and SWSAP1 c.353del indicated a partial decrease or absence of IH-HR activity in Sws1−/− or Swsap1−/− cells, respectively, and destabilization of the SWSAP1 truncation mutant. LIMITATIONS, REASONS FOR CAUTION: Identification of other patients carrying SWSAP1 variants is needed to evaluate in-depth phenotype to genotype correlations. Future studies should evaluate the role of other genes in the SWS1-complex and explore the potential for therapeutic interventions targeting homologous recombination. WIDER IMPLICATIONS OF THE FINDINGS: These findings provide direct clinical and functional evidence that all three members of the SWS1-complex are implicated in female fertility and recapitulate the observed mouse phenotypes. IH-HR assays provide a relevant functional approach to validate novel variants in homologous recombination genes for POI patients, given the importance of IH-HR for meiotic progression. STUDY FUNDING/COMPETING INTEREST(S): The French Genomic Medicine Initiative PFMG2025 is supported by grants from the French government, notably by the French National Research Agency under the Programme d’Investissments d’Avenir for the CAD (ANR-21-ESRE0001) and the CRefIX (ANR-10-INBS-09-01). M.J. was supported by R01 HD112624 and R35CA253174 grants. E.J.T. was supported by a Norman Beischer Fellowship and a Centre for Research Excellence for Women’s Health in Reproductive Life (CRE-WHiRL) fellowship from the National Health and Medical Research Council (NHMRC). J.F.M. was supported by a Research Training Program scholarship from the Australian Government. The authors declare no competing interests. TRIAL REGISTRATION NUMBER: This manuscript included genomic analysis performed in clinical practice in patients with RD/CGP and cancers in France. Consequently, a clinical trial NCT number was not required as we reported in this manuscript results obtained in clinical practice. In compliance with the French law on bioethics (2004-800, 06/08/2004), patients had signed written informed consent forms for clinical practice and had been informed of the research use of what remained of their samples after establishing the molecular diagnosis.
- 24 September 2025
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 40 (11) , 2189-2201
SWS1-complex in premature ovarian insufficiency: SWSAP1 as a new POI gene
STUDY QUESTION: What other zinc finger SWIM domain-containing protein 7 (SWS1/ZSWIM7) partners are involved in premature ovarian insufficiency (POI)? SUMMARY ANSWER: This study identifies novel pathogenic variants in zinc finger SWIM domain-containing protein 7 (SWS1/ZSWIM7) and its partner, SWSAP1, which impair interhomolog homologous recombination (IH-HR) and lead to isolated POI. WHAT IS KNOWN ALREADY: Knockout mice models of the SWS1-complex (also known as the SWS1–SWSAP1–SPIDR complex or Shu complex) are infertile due to meiotic arrest. Variants of both SWS1/ZSWIM7 and SPIDR are described in POI, but so far, no SWSAP1 variants have been described in female infertility. STUDY DESIGN, SIZE, DURATION: Screening for SWS1-complex variants was performed using exome or genome sequencing data from women with POI as ongoing patient care. In silico modelling, IH-HR assays, and western-blot analysis were performed to test the impact of novel variants identified in genes of the SWS1-complex (SWSAP1 and SWS1/ZSWIM7) on homologous recombination, protein expression, and protein interactions. PARTICIPANTS/MATERIALS, SETTING, METHODS: Five unrelated patients from France were enrolled based on their exome or genome sequencing result as part of ongoing patient care. All the patients were diagnosed with POI and met the European Society of Human Reproduction and Embryology (ESHRE) diagnostic criteria for POI. Functional validation was performed using mouse embryonic stem cells to study the impact of two novel variants found in two patients. MAIN RESULTS AND THE ROLE OF CHANCE: We report five different pathogenic or likely pathogenic variants in five patients. We report the previously described c.231_232del and c.176C>T variants in SWS1/ZSWIM7, as well as two novel variants, c.22del and c.151C>T. Additionally, we report a homozygous frameshift deletion in SWSAP1 (c.353del). All the patients display a similar phenotype of severe isolated POI, associated with primary or early secondary amenorrhea and signs of puberty delay. In silico modelling and IH-HR assays of both SWS1/ZSWIM7 c.176C>T and SWSAP1 c.353del indicated a partial decrease or absence of IH-HR activity in Sws1−/− or Swsap1−/− cells, respectively, and destabilization of the SWSAP1 truncation mutant. LIMITATIONS, REASONS FOR CAUTION: Identification of other patients carrying SWSAP1 variants is needed to evaluate in-depth phenotype to genotype correlations. Future studies should evaluate the role of other genes in the SWS1-complex and explore the potential for therapeutic interventions targeting homologous recombination. WIDER IMPLICATIONS OF THE FINDINGS: These findings provide direct clinical and functional evidence that all three members of the SWS1-complex are implicated in female fertility and recapitulate the observed mouse phenotypes. IH-HR assays provide a relevant functional approach to validate novel variants in homologous recombination genes for POI patients, given the importance of IH-HR for meiotic progression. STUDY FUNDING/COMPETING INTEREST(S): The French Genomic Medicine Initiative PFMG2025 is supported by grants from the French government, notably by the French National Research Agency under the Programme d’Investissments d’Avenir for the CAD (ANR-21-ESRE0001) and the CRefIX (ANR-10-INBS-09-01). M.J. was supported by R01 HD112624 and R35CA253174 grants. E.J.T. was supported by a Norman Beischer Fellowship and a Centre for Research Excellence for Women’s Health in Reproductive Life (CRE-WHiRL) fellowship from the National Health and Medical Research Council (NHMRC). J.F.M. was supported by a Research Training Program scholarship from the Australian Government. The authors declare no competing interests. TRIAL REGISTRATION NUMBER: This manuscript included genomic analysis performed in clinical practice in patients with RD/CGP and cancers in France. Consequently, a clinical trial NCT number was not required as we reported in this manuscript results obtained in clinical practice. In compliance with the French law on bioethics (2004-800, 06/08/2004), patients had signed written informed consent forms for clinical practice and had been informed of the research use of what remained of their samples after establishing the molecular diagnosis.
- 5 June 2024
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 190 (6) , 501-508
Gonadotropic status in adult women with pituitary stalk interruption syndrome
Objective: Pituitary stalk interruption syndrome (PSIS) is a rare cause of congenital hypopituitarism. Limited data exist on the gonadotropic status and fertility of adult women with PSIS. Our study aims to describe pubertal development and the evolution of gonadotropic function and fertility in adult women with PSIS. Design: A retrospective multicentric French study. Methods: We described gonadotropic function in 56 adult women with PSIS from puberty onward. We compared live birth rates per woman with PSIS with age-matched controls from the large French epidemiological cohort (CONSTANCES). Additionally, we assessed height, body mass index (BMI), blood pressure, other metabolic parameters, and socioeconomic status. Results and Conclusions: Among 56 women with PSIS, 36 did not experience spontaneous puberty. Of these, 13 underwent ovarian stimulation, resulting in 7 women having a total of 11 children. In the subgroup with spontaneous puberty (n = 20), 4 had a total of 8 pregnancies, while 6 developed secondary gonadotropic deficiency. Women with PSIS had fewer children than controls (0.33 vs 0.63, P = .04). Median height was also lower (160.5 vs 165.0 cm, P < .0001). Although mean blood pressure was lower in women with PSIS compared with controls (111.3/65.9 ± 11.2/8.1 vs 118.7/72.1 ± 10.1/7.7 mmHg, P < .001), there were no significant differences in other metabolic parameters, notably BMI and lipid profile. Employment/academic status was not different in the 2 groups, but fewer women with PSIS were in relationships (42% vs 57.6% in controls, P = .02). The fertility prognosis in patients with PSIS needs optimization. Patients should be informed about the likelihood of declining gonadotropic function over time.
- 5 June 2024
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 190 (6) , 501-508
Gonadotropic status in adult women with pituitary stalk interruption syndrome
Objective: Pituitary stalk interruption syndrome (PSIS) is a rare cause of congenital hypopituitarism. Limited data exist on the gonadotropic status and fertility of adult women with PSIS. Our study aims to describe pubertal development and the evolution of gonadotropic function and fertility in adult women with PSIS. Design: A retrospective multicentric French study. Methods: We described gonadotropic function in 56 adult women with PSIS from puberty onward. We compared live birth rates per woman with PSIS with age-matched controls from the large French epidemiological cohort (CONSTANCES). Additionally, we assessed height, body mass index (BMI), blood pressure, other metabolic parameters, and socioeconomic status. Results and Conclusions: Among 56 women with PSIS, 36 did not experience spontaneous puberty. Of these, 13 underwent ovarian stimulation, resulting in 7 women having a total of 11 children. In the subgroup with spontaneous puberty (n = 20), 4 had a total of 8 pregnancies, while 6 developed secondary gonadotropic deficiency. Women with PSIS had fewer children than controls (0.33 vs 0.63, P = .04). Median height was also lower (160.5 vs 165.0 cm, P < .0001). Although mean blood pressure was lower in women with PSIS compared with controls (111.3/65.9 ± 11.2/8.1 vs 118.7/72.1 ± 10.1/7.7 mmHg, P < .001), there were no significant differences in other metabolic parameters, notably BMI and lipid profile. Employment/academic status was not different in the 2 groups, but fewer women with PSIS were in relationships (42% vs 57.6% in controls, P = .02). The fertility prognosis in patients with PSIS needs optimization. Patients should be informed about the likelihood of declining gonadotropic function over time.
- Top Cited PapersOpen Access
- 15 May 2024
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 190 (6) , G53-G151
Clinical practice guidelines for the care of girls and women with Turner syndrome
Turner syndrome (TS) affects 50 per 100 000 females. TS affects multiple organs through all stages of life, necessitating multidisciplinary care. This guideline extends previous ones and includes important new advances, within diagnostics and genetics, estrogen treatment, fertility, co-morbidities, and neurocognition and neuropsychology. Exploratory meetings were held in 2021 in Europe and United States culminating with a consensus meeting in Aarhus, Denmark in June 2023. Prior to this, eight groups addressed important areas in TS care: (1) diagnosis and genetics, (2) growth, (3) puberty and estrogen treatment, (4) cardiovascular health, (5) transition, (6) fertility assessment, monitoring, and counselling, (7) health surveillance for comorbidities throughout the lifespan, and (8) neurocognition and its implications for mental health and well-being. Each group produced proposals for the present guidelines, which were meticulously discussed by the entire group. Four pertinent questions were submitted for formal GRADE (Grading of Recommendations, Assessment, Development and Evaluation) evaluation with systematic review of the literature. The guidelines project was initiated by the European Society for Endocrinology and the Pediatric Endocrine Society, in collaboration with members from the European Society for Pediatric Endocrinology, the European Society of Human Reproduction and Embryology, the European Reference Network on Rare Endocrine Conditions, the Society for Endocrinology, and the European Society of Cardiology, Japanese Society for Pediatric Endocrinology, Australia and New Zealand Society for Pediatric Endocrinology and Diabetes, Latin American Society for Pediatric Endocrinology, Arab Society for Pediatric Endocrinology and Diabetes, and the Asia Pacific Pediatric Endocrine Society. Advocacy groups appointed representatives for pre-meeting discussions and the consensus meeting.
- 15 May 2024
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 190 (6) , G53-G151
Top Cited PapersOpen AccessClinical practice guidelines for the care of girls and women with Turner syndrome
Turner syndrome (TS) affects 50 per 100 000 females. TS affects multiple organs through all stages of life, necessitating multidisciplinary care. This guideline extends previous ones and includes important new advances, within diagnostics and genetics, estrogen treatment, fertility, co-morbidities, and neurocognition and neuropsychology. Exploratory meetings were held in 2021 in Europe and United States culminating with a consensus meeting in Aarhus, Denmark in June 2023. Prior to this, eight groups addressed important areas in TS care: (1) diagnosis and genetics, (2) growth, (3) puberty and estrogen treatment, (4) cardiovascular health, (5) transition, (6) fertility assessment, monitoring, and counselling, (7) health surveillance for comorbidities throughout the lifespan, and (8) neurocognition and its implications for mental health and well-being. Each group produced proposals for the present guidelines, which were meticulously discussed by the entire group. Four pertinent questions were submitted for formal GRADE (Grading of Recommendations, Assessment, Development and Evaluation) evaluation with systematic review of the literature. The guidelines project was initiated by the European Society for Endocrinology and the Pediatric Endocrine Society, in collaboration with members from the European Society for Pediatric Endocrinology, the European Society of Human Reproduction and Embryology, the European Reference Network on Rare Endocrine Conditions, the Society for Endocrinology, and the European Society of Cardiology, Japanese Society for Pediatric Endocrinology, Australia and New Zealand Society for Pediatric Endocrinology and Diabetes, Latin American Society for Pediatric Endocrinology, Arab Society for Pediatric Endocrinology and Diabetes, and the Asia Pacific Pediatric Endocrine Society. Advocacy groups appointed representatives for pre-meeting discussions and the consensus meeting.
- Top Cited Papers
- 10 April 2024
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 39 (6) , 1167-1175
Epigenetic/circadian clocks and PCOS
Polycystic ovary syndrome (PCOS) affects 6–20% of reproductive-aged women. It is associated with increased risks of metabolic syndrome, Type 2 diabetes, cardiovascular diseases, mood disorders, endometrial cancer and non-alcoholic fatty liver disease. Although various susceptibility loci have been identified through genetic studies, they account for ∼10% of PCOS heritability. Therefore, the etiology of PCOS remains unclear. This review explores the role of epigenetic changes and modifications in circadian clock genes as potential contributors to PCOS pathogenesis. Epigenetic alterations, such as DNA methylation, histone modifications, and non-coding RNA changes, have been described in diseases related to PCOS, such as diabetes, cardiovascular diseases, and obesity. Furthermore, several animal models have illustrated a link between prenatal exposure to androgens or anti-Müllerian hormone and PCOS-like phenotypes in subsequent generations, illustrating an epigenetic programming in PCOS. In humans, epigenetic changes have been reported in peripheral blood mononuclear cells (PBMC), adipose tissue, granulosa cells (GC), and liver from women with PCOS. The genome of women with PCOS is globally hypomethylated compared to healthy controls. However, specific hypomethylated or hypermethylated genes have been reported in the different tissues of these women. They are mainly involved in hormonal regulation and inflammatory pathways, as well as lipid and glucose metabolism. Additionally, sleep disorders are present in women with PCOS and disruptions in clock genes’ expression patterns have been observed in their PBMC or GCs. While epigenetic changes hold promise as diagnostic biomarkers, the current challenge lies in distinguishing whether these changes are causes or consequences of PCOS. Targeting epigenetic modifications potentially opens avenues for precision medicine in PCOS, including lifestyle interventions and drug therapies. However, data are still lacking in large cohorts of well-characterized PCOS phenotypes. In conclusion, understanding the interplay between genetics, epigenetics, and circadian rhythms may provide valuable insights for early diagnosis and therapeutic strategies in PCOS in the future.
- 10 April 2024
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 39 (6) , 1167-1175
Top Cited PapersEpigenetic/circadian clocks and PCOS
Polycystic ovary syndrome (PCOS) affects 6–20% of reproductive-aged women. It is associated with increased risks of metabolic syndrome, Type 2 diabetes, cardiovascular diseases, mood disorders, endometrial cancer and non-alcoholic fatty liver disease. Although various susceptibility loci have been identified through genetic studies, they account for ∼10% of PCOS heritability. Therefore, the etiology of PCOS remains unclear. This review explores the role of epigenetic changes and modifications in circadian clock genes as potential contributors to PCOS pathogenesis. Epigenetic alterations, such as DNA methylation, histone modifications, and non-coding RNA changes, have been described in diseases related to PCOS, such as diabetes, cardiovascular diseases, and obesity. Furthermore, several animal models have illustrated a link between prenatal exposure to androgens or anti-Müllerian hormone and PCOS-like phenotypes in subsequent generations, illustrating an epigenetic programming in PCOS. In humans, epigenetic changes have been reported in peripheral blood mononuclear cells (PBMC), adipose tissue, granulosa cells (GC), and liver from women with PCOS. The genome of women with PCOS is globally hypomethylated compared to healthy controls. However, specific hypomethylated or hypermethylated genes have been reported in the different tissues of these women. They are mainly involved in hormonal regulation and inflammatory pathways, as well as lipid and glucose metabolism. Additionally, sleep disorders are present in women with PCOS and disruptions in clock genes’ expression patterns have been observed in their PBMC or GCs. While epigenetic changes hold promise as diagnostic biomarkers, the current challenge lies in distinguishing whether these changes are causes or consequences of PCOS. Targeting epigenetic modifications potentially opens avenues for precision medicine in PCOS, including lifestyle interventions and drug therapies. However, data are still lacking in large cohorts of well-characterized PCOS phenotypes. In conclusion, understanding the interplay between genetics, epigenetics, and circadian rhythms may provide valuable insights for early diagnosis and therapeutic strategies in PCOS in the future.
- 3 November 2023
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 41 (1) , 135-146
NOBOX gene variants in premature ovarian insufficiency: ethnicity-dependent insights
Purpose Premature ovarian insufficiency (POI) affects approximately 1% of women before the age of 40. Genetic contribution is a significant component of POI. The NOBOX gene was considered one of the major genetic causes of POI. However, the pathogenicity and the penetrance of NOBOX variants remain unclear. Methods We studied the whole coding region of the NOBOX gene by next generation sequencing in a cohort of 810 patients with POI, and we compared the frequency of each identified NOBOX variant to the general population taking into account the ethnicity of each individual. Results Screening of the whole coding region of the NOBOX gene allowed us to identify 35 different variants, including 5 loss-of-function variants. In total, 171 patients with POI (25%) carried out at least one NOBOX variant. Regarding missense variants, we observed a significant overrepresentation of the most frequent ones in our 810 POI patients as compared to the general, except for p.(Arg117Trp). However, taking into account the ethnic origin of the individuals, we observed no significant OR difference for p.(Arg44Leu) and p.(Arg117Trp) in African subgroup and for p.(Asp452Asn) in European subgroup. Conclusion This population study suggests that the p.(Arg44Leu) variant could be considered benign variant and that the p.(Asp452Asn) and p.(Arg117Trp) variants could be considered moderate risk pathogenic variants with probably partial and very low penetrance and/or expressivity. In contrast, p.(Gly91Trp) and p.(Gly152Arg) variants could be considered pathogenic variants with a moderate functional impact.
- 3 November 2023
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 41 (1) , 135-146
NOBOX gene variants in premature ovarian insufficiency: ethnicity-dependent insights
Purpose Premature ovarian insufficiency (POI) affects approximately 1% of women before the age of 40. Genetic contribution is a significant component of POI. The NOBOX gene was considered one of the major genetic causes of POI. However, the pathogenicity and the penetrance of NOBOX variants remain unclear. Methods We studied the whole coding region of the NOBOX gene by next generation sequencing in a cohort of 810 patients with POI, and we compared the frequency of each identified NOBOX variant to the general population taking into account the ethnicity of each individual. Results Screening of the whole coding region of the NOBOX gene allowed us to identify 35 different variants, including 5 loss-of-function variants. In total, 171 patients with POI (25%) carried out at least one NOBOX variant. Regarding missense variants, we observed a significant overrepresentation of the most frequent ones in our 810 POI patients as compared to the general, except for p.(Arg117Trp). However, taking into account the ethnic origin of the individuals, we observed no significant OR difference for p.(Arg44Leu) and p.(Arg117Trp) in African subgroup and for p.(Asp452Asn) in European subgroup. Conclusion This population study suggests that the p.(Arg44Leu) variant could be considered benign variant and that the p.(Asp452Asn) and p.(Arg117Trp) variants could be considered moderate risk pathogenic variants with probably partial and very low penetrance and/or expressivity. In contrast, p.(Gly91Trp) and p.(Gly152Arg) variants could be considered pathogenic variants with a moderate functional impact.
- 1 July 2023
- Published by JLE in Médecine de la Reproduction
- Vol. 25 (3) , 303-321
Update on the genetics of premature ovarian insufficiency
- 1 July 2023
- Published by JLE in Médecine de la Reproduction
- Vol. 25 (3) , 303-321
Update on the genetics of premature ovarian insufficiency
- Open Access
- 24 May 2022
- Published by EDP Sciences in médecine/sciences
- Vol. 38 (5) , 457-463
La contraception à travers le monde
Les dernières données concernant la contraception à travers le monde ont été publiées en 2019 par l’Organisation des Nations unies (ONU). Parmi les 1,9 milliard de femmes en âge de procréer (entre 15 et 49 ans), 1,1 milliard souhaitaient une contraception. Pourtant, 10 % d’entre elles n’utilisaient pas de méthode contraceptive, essentiellement en raison d’un manque d’accès à ces méthodes. Selon les continents, une grande disparité est observée dans l’utilisation des différentes méthodes contraceptives. La stérilisation féminine, ou contraception définitive, reste cependant la méthode majoritairement utilisée puisqu’elle représente 24 % des contraceptions. Des progrès sont nécessaires, en particulier dans l’éducation, pour améliorer la diffusion d’autres méthodes également efficaces, qui sont bien tolérées et possiblement réversibles.
- 24 May 2022
- Published by EDP Sciences in médecine/sciences
- Vol. 38 (5) , 457-463
Open AccessLa contraception à travers le monde
Les dernières données concernant la contraception à travers le monde ont été publiées en 2019 par l’Organisation des Nations unies (ONU). Parmi les 1,9 milliard de femmes en âge de procréer (entre 15 et 49 ans), 1,1 milliard souhaitaient une contraception. Pourtant, 10 % d’entre elles n’utilisaient pas de méthode contraceptive, essentiellement en raison d’un manque d’accès à ces méthodes. Selon les continents, une grande disparité est observée dans l’utilisation des différentes méthodes contraceptives. La stérilisation féminine, ou contraception définitive, reste cependant la méthode majoritairement utilisée puisqu’elle représente 24 % des contraceptions. Des progrès sont nécessaires, en particulier dans l’éducation, pour améliorer la diffusion d’autres méthodes également efficaces, qui sont bien tolérées et possiblement réversibles.